Abstract

Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) has been used in children with von Willebrand disease (VWD) and Hemophilia A for almost 35 years. This treatment has substantially lowered the number of children exposed to human plasma derived products, with a good safety profile, and at very low cost. The response to DDAVP has been shown to be associated with age, baseline factor level, and genetic mutations. A DDAVP challenge test is recommended. DDAVP has also been used to prevent and treat bleeding episodes in children with platelet function defects and other disorders associated with bleeding tendency.

Keywords

MedicineIntensive care medicineRandomized controlled trialClinical trialFactor VIIaRecombinant factor VIIaPediatricsSurgeryInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2013
Type
article
Volume
60 Suppl 1
Pages
42-66
Citations
3514
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3514
OpenAlex

Cite This

Shoshana Revel‐Vilk, Peter N. Cox, Nancy Robitaille et al. (2013). Hematological Problems in Pediatric Intensive Care. Pediatric and adolescent medicine , 60 Suppl 1 , 42-66. https://doi.org/10.1159/000350346

Identifiers

DOI
10.1159/000350346